Quoc-Dien Trinh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9028125/publications.pdf

Version: 2024-02-01

653 papers

19,565 citations

69 h-index 30848 102 g-index

661 all docs

661 docs citations

661 times ranked

16378 citing authors

#	Article	IF	CITATIONS
1	Multi-Institutional Validation of a New Renal Cancer–Specific Survival Nomogram. Journal of Clinical Oncology, 2007, 25, 1316-1322.	0.8	470
2	Perioperative Outcomes of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy: Results From the Nationwide Inpatient Sample. European Urology, 2012, 61, 679-685.	0.9	345
3	Small renal masses progressing to metastases under active surveillance. Cancer, 2012, 118, 997-1006.	2.0	332
4	Propensity-Matched Comparison of Morbidity and Costs of Open and Robot-Assisted Radical Cystectomies: A Contemporary Population-Based Analysis in the United States. European Urology, 2014, 66, 569-576.	0.9	205
5	Lack of reduction in racial disparities in cancerâ€specific mortality over a 20â€year period. Cancer, 2014, 120, 1532-1539.	2.0	204
6	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. European Urology, 2014, 65, 210-217.	0.9	201
7	Practice Patterns and Outcomes of Open and Minimally Invasive Partial Nephrectomy Since the Introduction of Robotic Partial Nephrectomy: Results from the Nationwide Inpatient Sample. Journal of Urology, 2014, 191, 907-913.	0.2	197
8	Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. Journal of Clinical Oncology, 2016, 34, 3267-3275.	0.8	185
9	Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. European Urology, 2016, 70, 837-845.	0.9	178
10	Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. JAMA Oncology, 2021, 7, 458.	3.4	177
11	A Systematic Review of the Volume–Outcome Relationship for Radical Prostatectomy. European Urology, 2013, 64, 786-798.	0.9	172
12	Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era. Journal of Clinical Oncology, 2014, 32, 1419-1426.	0.8	169
13	Câ€reactive protein is an informative predictor of renal cell carcinomaâ€specific mortality. Cancer, 2007, 110, 1241-1247.	2.0	165
14	Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. International Journal of Cancer, 2008, 123, 395-400.	2.3	159
15	Venous Thromboembolism After Major Cancer Surgery. JAMA Surgery, 2014, 149, 43.	2.2	158
16	Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. European Urology, 2014, 66, 156-163.	0.9	156
17	Neoadjuvant chemotherapy prior to radical cystectomy for muscleâ€invasive bladder cancer with variant histology. Cancer, 2017, 123, 4346-4355.	2.0	138
18	Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study. European Urology, 2015, 67, 3-6.	0.9	136

#	Article	IF	CITATIONS
19	Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. European Urology, 2014, 65, 650-658.	0.9	134
20	Clinicians are poor raters of lifeâ€expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU International, 2007, 100, 1254-1258.	1.3	129
21	Chronic Kidney Disease After Nephrectomy in Patients with Small Renal Masses: A Retrospective Observational Analysis. European Urology, 2012, 62, 696-703.	0.9	129
22	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroâ€ureterectomy. BJU International, 2013, 112, 453-461.	1.3	128
23	The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. European Urology, 2017, 72, 14-19.	0.9	128
24	A Non–Cancer-Related Survival Benefit Is Associated With Partial Nephrectomy. European Urology, 2012, 61, 725-731.	0.9	124
25	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1905-1912.	0.8	121
26	Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer, 2007, 109, 868-874.	2.0	115
27	Safety Profile of Robot-Assisted Radical Prostatectomy: A Standardized Report of Complications in 3317 Patients. European Urology, 2011, 59, 684-698.	0.9	114
28	Cancer-Specific Outcomes Among Young Adults Without Health Insurance. Journal of Clinical Oncology, 2014, 32, 2025-2030.	0.8	112
29	Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. European Urology, 2021, 79, 595-604.	0.9	111
30	Management of Localized Kidney Cancer: Calculating Cancer-specific Mortality and Competing Risks of Death for Surgery and Nonsurgical Management. European Urology, 2014, 65, 235-241.	0.9	110
31	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. European Urology, 2017, 72, 483-487.	0.9	110
32	Effect of Minimally Invasive Surgery on the Risk for Surgical Site Infections. JAMA Surgery, 2014, 149, 1039.	2.2	109
33	A Review of Integrated Staging Systems for Renal Cell Carcinoma. European Urology, 2012, 62, 303-314.	0.9	108
34	Standardized assessment of complications in a contemporary series of <scp>E</scp> uropean patients undergoing radical cystectomy. International Journal of Urology, 2014, 21, 143-149.	0.5	106
35	Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. JAMA - Journal of the American Medical Association, 2015, 314, 2077.	3.8	105
36	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2017, 35, 852-860.	0.8	104

#	Article	IF	CITATIONS
37	Polymorphism, shared functions and convergent evolution of genes with sequences coding for polyalanine domains. Human Molecular Genetics, 2003, 12, 2967-2979.	1.4	103
38	Off-clamp Robot-assisted Partial Nephrectomy Preserves Renal Function: A Multi-institutional Propensity Score Analysis. European Urology, 2013, 64, 988-993.	0.9	101
39	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. European Urology, 2013, 64, 456-464.	0.9	101
40	Racial/Ethnic Disparities in Perioperative Outcomes of Major Procedures. Annals of Surgery, 2015, 262, 955-964.	2.1	101
41	Incompletely Characterized Incidental Renal Masses: Emerging Data Support Conservative Management. Radiology, 2015, 275, 28-42.	3.6	98
42	Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. European Urology, 2014, 66, 666-672.	0.9	97
43	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. JAMA Oncology, 2016, 2, 500.	3.4	94
44	Renal Cell Carcinoma with Nodal Metastases in the Absence of Distant Metastatic Disease: Prognostic Indicators of Disease-Specific Survival. European Urology, 2007, 51, 1616-1624.	0.9	93
45	Treatment Management of Small Renal Masses in the 21st Century: A Paradigm Shift. Annals of Surgical Oncology, 2012, 19, 2380-2387.	0.7	91
46	Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. European Urology, 2017, 72, 64-75.	0.9	91
47	Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer. Cancer, 2017, 123, 3241-3252.	2.0	89
48	Collecting Duct Renal Cell Carcinoma: A Matched Analysis of 41 Cases. European Urology, 2007, 52, 1140-1146.	0.9	88
49	Emergency Department Visits in the United States for Upper Urinary Tract Stones: Trends in Hospitalization and Charges. Journal of Urology, 2014, 191, 90-96.	0.2	88
50	Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. JAMA Network Open, 2020, 3, e2030072.	2.8	87
51	Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface–Intermediate–Base Margin Score. European Urology, 2014, 66, 803-805.	0.9	86
52	Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups. Urology, 2014, 84, 386-392.	0.5	86
53	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncology, 2016, 2, 85.	3.4	86
54	Robot-Assisted Versus Open Radical Prostatectomy: The Differential Effect of Regionalization, Procedure Volume and Operative Approach. Journal of Urology, 2013, 189, 1289-1294.	0.2	81

#	Article	IF	CITATIONS
55	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1285-1291.	0.8	81
56	Trends in Percutaneous Nephrolithotomy Use and Outcomes in the United States. Journal of Urology, 2013, 190, 558-564.	0.2	80
57	Renal Mass Biopsy: Always, Sometimes, or Never?. European Urology, 2016, 70, 403-406.	0.9	80
58	Impact of surgeon volume on the morbidity and costs of radical cystectomy in the <scp>USA</scp> : a contemporary populationâ€based analysis. BJU International, 2015, 115, 713-721.	1.3	79
59	Contemporary incidence and mortality rates of kidney cancer in the United States. Canadian Urological Association Journal, 2014, 8, 247.	0.3	78
60	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. Journal of Clinical Oncology, 2019, 37, 923-931.	0.8	78
61	Predictors of cancerâ€specific mortality after disease recurrence following radical cystectomy. BJU International, 2013, 111, E30-6.	1.3	77
62	The impact of androgenâ€deprivation therapy (<scp>ADT</scp>) on the risk of cardiovascular (<scp>CV</scp>) events in patients with nonâ€metastatic prostate cancer: a populationâ€based study. BJU International, 2014, 114, E82-E89.	1.3	77
63	Racial Disparities in Operative Outcomes After Major Cancer Surgery in the United States. World Journal of Surgery, 2015, 39, 634-643.	0.8	76
64	Incidence of Priapism in Emergency Departments in the United States. Journal of Urology, 2013, 190, 1275-1280.	0.2	75
65	Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. European Urology Oncology, 2019, 2, 265-273.	2.6	75
66	Engaging responsibly with social media: the <scp>BJUI</scp> guidelines. BJU International, 2014, 114, 9-11.	1.3	74
67	Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 61-68.	2.3	72
68	Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. European Urology, 2016, 69, 775-787.	0.9	72
69	Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladderâ€preservation therapy for muscleâ€invasive bladder cancer. Cancer, 2017, 123, 4337-4345.	2.0	72
70	Robotic ultrasound probe for tumor identification in robotic partial nephrectomy: Initial series and outcomes. International Journal of Urology, 2013, 20, 172-176.	0.5	71
71	Temporal Trends, Practice Patterns, and Treatment Outcomes for Infected Upper Urinary Tract Stones in the United States. European Urology, 2013, 64, 85-92.	0.9	71
72	BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers. Current Opinion in Molecular Therapeutics, 2010, 12, 607-16.	2.8	71

#	Article	IF	Citations
73	Growth Kinetics and Short-Term Outcomes of cT1b and cT2 Renal Masses under Active Surveillance. Journal of Urology, 2014, 192, 659-664.	0.2	70
74	The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. European Urology, 2014, 66, 561-568.	0.9	70
75	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score–Weighted Analysis From the National Cancer Data Base. Journal of Clinical Oncology, 2016, 34, 3529-3536.	0.8	70
76	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Journal of Urology, 2018, 199, 1417-1425.	0.2	70
77	Impact of smoking on perioperative outcomes after major surgery. American Journal of Surgery, 2015, 210, 221-229.e6.	0.9	69
78	The Effect of Body Mass Index on Perioperative Outcomes After Major Surgery: Results from the National Surgical Quality Improvement Program (ACSâ€NSQIP) 2005–2011. World Journal of Surgery, 2015, 39, 2376-2385.	0.8	69
79	Heterogeneity and renal mass biopsy: a review of its role and reliability. Cancer Biology and Medicine, 2014, 11, 162-72.	1.4	69
80	Systematic Review of the Volume–Outcome Relationship for Radical Prostatectomy. European Urology Focus, 2018, 4, 775-789.	1.6	68
81	Association of androgenâ€deprivation therapy with excess cardiacâ€specific mortality in men with prostate cancer. BJU International, 2015, 116, 358-365.	1.3	66
82	Disparities in access to care at highâ€volume institutions for uroâ€oncologic procedures. Cancer, 2012, 118, 4421-4426.	2.0	65
83	Propensity-Score-Matched Comparison of Perioperative Outcomes Between Open and Laparoscopic Nephroureterectomy: A National Series. European Urology, 2012, 61, 715-721.	0.9	65
84	Prospective randomized trial of barbed polyglyconate suture to facilitate vesicoâ€urethral anastomosis during robotâ€assisted radical prostatectomy: time reduction and cost benefit. BJU International, 2012, 109, 1526-1532.	1.3	65
85	Trends in surgery for upper urinary tract calculi in the <scp>USA</scp> using the <scp>N</scp> ationwide <scp>I</scp> npatient <scp>S</scp> ample: 1999–2009. BJU International, 2013, 112, 224-230.	1.3	65
86	Morbidity and Mortality After Benign Prostatic Hyperplasia Surgery: Data from the American College of Surgeons National Surgical Quality Improvement Program. Journal of Endourology, 2014, 28, 831-840.	1.1	64
87	Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy. Urology, 2015, 86, 300-306.	0.5	64
88	Assessing the Burden of Complications After Surgery for Clinically Localized Kidney Cancer by Age and Comorbidity Status. Urology, 2014, 83, 843-850.	0.5	63
89	Cancer-Specific Mortality of Asian Americans Diagnosed With Cancer: A Nationwide Population-Based Assessment. Journal of the National Cancer Institute, 2015, 107, djv054-djv054.	3.0	63
90	The influence of marital status on the use of breast, cervical, and colorectal cancer screening. Preventive Medicine, 2016, 89, 140-145.	1.6	63

#	Article	lF	CITATIONS
91	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. European Urology, 2018, 73, 374-382.	0.9	62
92	Radiation Safety Knowledge and Practices Among Urology Residents and Fellows: Results of a Nationwide Survey. Journal of Surgical Education, 2013, 70, 224-231.	1.2	61
93	Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU International, 2014, 113, 200-208.	1.3	61
94	A Population-Based Assessment of the Burden of Acute Pancreatitis in the United States. Pancreas, 2014, 43, 687-691.	0.5	61
95	Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. Journal of Urology, 2020, 203, 496-504.	0.2	61
96	Association of Care at Minority-Serving vs Non–Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. JAMA Network Open, 2019, 2, e187633.	2.8	60
97	Mental health outcomes in elderly men with prostate cancer1Equal contribution Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1333-1340.	0.8	59
98	Variation in Surgical Margin Status by Surgical Approach among Patients Undergoing Partial Nephrectomy for Small Renal Masses. Journal of Urology, 2015, 194, 1548-1553.	0.2	59
99	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. European Urology Oncology, 2018, 1, 83-90.	2.6	59
100	Hospital Volume is a Determinant of Postoperative Complications, Blood Transfusion and Length of Stay After Radical or Partial Nephrectomy. Journal of Urology, 2012, 187, 405-410.	0.2	58
101	Disparities in Access to Hospitals with Robotic Surgery for Patients with Prostate Cancer Undergoing Radical Prostatectomy. Journal of Urology, 2013, 189, 514-520.	0.2	57
102	Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. European Urology, 2015, 68, 756-765.	0.9	57
103	Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. JAMA Dermatology, 2021, 157, 35.	2.0	57
104	Anastomosis During Robot-assisted Radical Prostatectomy: Randomized Controlled Trial Comparing Barbed and Standard Monofilament Suture. Urology, 2011, 78, 572-579.	0.5	56
105	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscleâ€invasive carcinoma of the bladder: Does histologic subtype matter?. Cancer, 2019, 125, 1449-1458.	2.0	56
106	Comparison of partial vs radical nephrectomy with regard to otherâ€cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. BJU International, 2013, 111, 67-73.	1.3	54
107	Treatment Trends and Outcomes for Patients With Lymph Node–Positive Cancer of the Penis. JAMA Oncology, 2018, 4, 643.	3.4	54
108	Assessing Performance Trends in Laparoscopic Nephrectomy and Nephron-sparing Surgery for Localized Renal Tumors. Urology, 2012, 80, 286-292.	0.5	53

#	Article	IF	Citations
109	Marital status: a genderâ€independent risk factor for poorer survival after radical cystectomy. BJU International, 2012, 110, 1301-1309.	1.3	53
110	Income inequality and treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 18.e7-18.e13.	0.8	53
111	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 125-136.	2.0	53
112	Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e1-88.e9.	0.8	52
113	In-hospital Mortality and Failure to Rescue After Cytoreductive Nephrectomy. European Urology, 2013, 63, 1107-1114.	0.9	51
114	Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database. Canadian Urological Association Journal, 2014, 8, 681.	0.3	51
115	Where Is the Value in Ambulatory Versus Inpatient Surgery?. Annals of Surgery, 2021, 273, 909-916.	2.1	51
116	Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. European Journal of Cancer, 2012, 48, 1503-1511.	1.3	50
117	Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1259-1266.	0.8	50
118	Photoselective Vaporization of the Prostate for Benign Prostatic Hyperplasia Using the 180 Watt System: Multicenter Study of the Impact of Prostate Size on Safety and Outcomes. Journal of Urology, 2015, 194, 462-469.	0.2	50
119	Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. European Urology, 2015, 68, 949-956.	0.9	50
120	Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. Current Urology Reports, 2017, 18, 15.	1.0	49
121	Is robotic surgery cost-effective. Current Opinion in Urology, 2012, 22, 61-65.	0.9	48
122	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer and Prostatic Diseases, 2018, 21, 364-372.	2.0	48
123	Secondary data sources for health services research in urologic oncology. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 165-173.	0.8	48
124	Effect of Medicaid Expansion on Colorectal Cancer Screening Rates. Diseases of the Colon and Rectum, 2019, 62, 97-103.	0.7	48
125	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. European Urology, 2013, 63, 371-378.	0.9	47
126	Predictors of Immediate Continence Following Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2013, 27, 442-446.	1.1	47

#	Article	IF	Citations
127	Predictors of early continence following robot-assisted radical prostatectomy. Canadian Urological Association Journal, 2015, 9, 93.	0.3	47
128	Does Partial Nephrectomy Result in a Durable Overall Survival Benefit in the Medicare Population?. Journal of Urology, 2012, 188, 2089-2094.	0.2	46
129	The impact of resident involvement in minimally-invasive urologic oncology procedures. Canadian Urological Association Journal, 2014, 8, 334.	0.3	46
130	Correction of Ureteropelvic Junction Obstruction in Children: National Trends and Comparative Effectiveness in Operative Outcomes. Journal of Endourology, 2014, 28, 592-598.	1.1	46
131	Racial Disparities in Prostate Cancer–Specific Mortality in Men With Low-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, e189-e195.	0.9	46
132	Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. European Urology, 2018, 73, 452-461.	0.9	46
133	Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. Journal of the National Cancer Institute, 2021, 113, 719-726.	3.0	45
134	National Trends and Disparities in the Use of Minimally Invasive Adult Pyeloplasty. Journal of Urology, 2012, 188, 913-918.	0.2	44
135	180 W vs 120 W Lithium Triborate Photoselective Vaporization of the Prostate for Benign Prostatic Hyperplasia: A Global, Multicenter Comparative Analysis of Perioperative Treatment Parameters. Urology, 2013, 82, 1108-1113.	0.5	44
136	Effect of metabolic syndrome on pathologic features of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1054-1059.	0.8	44
137	Hospitalization Costs for Radical Prostatectomy Attributable to Robotic Surgery. European Urology, 2013, 64, 11-16.	0.9	44
138	Incidence, admission rates, and economic burden of pediatric emergency department visits for urinary tract infection: Data from the nationwide emergency department sample, 2006 to 2011. Journal of Pediatric Urology, 2015, 11, 246.e1-246.e8.	0.6	44
139	Secondary data analysis. Current Opinion in Urology, 2017, 27, 354-359.	0.9	44
140	Complications After Metastasectomy for Renal Cell Carcinomaâ€"A Population-based Assessment. European Urology, 2017, 72, 171-174.	0.9	44
141	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. European Urology Focus, 2019, 5, 474-481.	1.6	44
142	A Stage-for-Stage and Grade-for-Grade Analysis of Cancer-Specific Mortality Rates in Renal Cell Carcinoma According to Age: A Competing-Risks Regression Analysis. European Urology, 2011, 60, 1152-1159.	0.9	43
143	Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. European Urology, 2015, 68, 32-39.	0.9	43
144	Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 293.e1-293.e10.	0.8	43

#	Article	IF	CITATIONS
145	Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy. Clinical Genitourinary Cancer, 2017, 15, 326-335.e3.	0.9	43
146	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. European Urology, 2018, 73, 445-451.	0.9	43
147	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. European Urology, 2019, 75, 399-407.	0.9	43
148	Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. European Urology, 2019, 75, 552-555.	0.9	43
149	Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses. European Urology Focus, 2019, 5, 77-80.	1.6	43
150	Clinical Implementation of Quality of Life Instruments and Prediction Tools for Localized Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Journal of Urology, 2013, 189, 2092-2098.	0.2	42
151	Robot-assisted versus laparoscopic nephroureterectomy for uppertract urothelial cancer: A population-based assessment of costs and perioperative outcomes. Canadian Urological Association Journal, 2014, 8, 695.	0.3	42
152	Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. Canadian Urological Association Journal, 2014, 8, 148.	0.3	42
153	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. Journal of Urology, 2016, 196, 1090-1095.	0.2	42
154	Active Surveillance for Low-Risk Prostate Cancer in Black Patients. New England Journal of Medicine, 2019, 380, 2070-2072.	13.9	42
155	Morbidity and mortality of radical prostatectomy differs by insurance status. Cancer, 2012, 118, 1803-1810.	2.0	41
156	Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. European Urology, 2018, 74, 387-393.	0.9	41
157	Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. Journal of Urology, 2013, 189, 468-473.	0.2	40
158	Variation in Pelvic Lymph Node Dissection among Patients Undergoing Radical Prostatectomy by Hospital Characteristics and Surgical Approach: Results from the National Cancer Database. Journal of Urology, 2015, 193, 820-825.	0.2	40
159	Definition and Validation of "Favorable High-Risk Prostate Cancer†Implications for Personalizing Treatment of Radiation-Managed Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 828-835.	0.4	40
160	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. European Urology, 2017, 71, 714-718.	0.9	40
161	Variation in the use of active surveillance for lowâ€risk prostate cancer. Cancer, 2018, 124, 55-64.	2.0	40
162	Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World Journal of Urology, 2019, 37, 2059-2065.	1.2	40

#	Article	IF	Citations
163	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. World Journal of Urology, 2013, 31, 5-11.	1.2	39
164	Testosterone Replacement Therapy Following the Diagnosis of Prostate Cancer: Outcomes and Utilization Trends. Journal of Sexual Medicine, 2014, 11, 1063-1070.	0.3	39
165	Is Robot-Assisted Radical Prostatectomy Safe in Men with High-Risk Prostate Cancer? Assessment of Perioperative Outcomes, Positive Surgical Margins, and Use of Additional Cancer Treatments. Journal of Endourology, 2014, 28, 784-791.	1.1	39
166	Suicide and accidental deaths among patients with nonâ€metastatic prostate cancer. BJU International, 2016, 118, 286-297.	1.3	39
167	Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer and Prostatic Diseases, 2020, 23, 81-87.	2.0	39
168	Unclassified renal cell carcinoma: an analysis of 85 cases. BJU International, 2007, 100, 802-808.	1.3	38
169	Development of a Highly Accurate Nomogram for Prediction of the Need for Exploration in Patients With Renal Trauma. Journal of Trauma, 2008, 64, 1451-1458.	2.3	38
170	Longâ€ŧerm followâ€up of patients undergoing percutaneous suprapubic tube drainage after robotâ€assisted radical prostatectomy (RARP). BJU International, 2012, 110, 580-585.	1.3	38
171	Trends in regionalization of radical cystectomy in three large northeastern states from 1996 to 2009. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1663-1669.	0.8	38
172	Active surveillance of small renal masses. Nature Reviews Urology, 2013, 10, 266-274.	1.9	37
173	Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data. BJU International, 2014, 113, 36-42.	1.3	37
174	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1131-1138.	2.3	37
175	Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ibâ€I renal masses: An analysis of the national cancer data base. Cancer, 2018, 124, 3839-3848.	2.0	37
176	Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 469.e1-469.e11.	0.8	37
177	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Network Open, 2020, 3, e201839.	2.8	37
178	Vattikuti Institute Prostatectomy—Technique in 2012. Journal of Endourology, 2012, 26, 1558-1565.	1,1	36
179	Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system. BMJ Open, 2014, 4, e003921.	0.8	36
180	The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. Journal of Surgical Education, 2015, 72, 1018-1025.	1.2	36

#	Article	IF	Citations
181	Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 388.e19-388.e25.	0.8	36
182	Causes of hospital readmissions after urologic cancer surgery. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 236.e1-236.e11.	0.8	36
183	Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data. Medical Care, 2017, 55, 398-404.	1.1	36
184	Minimally invasive vs open nephrectomy in the modern era: does approach matter?. World Journal of Urology, 2017, 35, 1557-1568.	1.2	36
185	Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy. BJU International, 2013, 111, 1208-1214.	1.3	35
186	Rates of open versus laparoscopic and partial versus radical nephrectomy for <scp>T</scp> 1a renal cell carcinoma: A populationâ€based evaluation. International Journal of Urology, 2013, 20, 1064-1071.	0.5	35
187	Radical Cystectomy in the Elderly: National Trends and Disparities in Perioperative Outcomes and Quality of Care. Urologia Internationalis, 2014, 92, 27-34.	0.6	35
188	Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. Clinical Genitourinary Cancer, 2015, 13, e123-e130.	0.9	35
189	Development and external validation of a prognostic tool for prediction of cancer-specific mortality after complete loco-regional pathological staging for squamous cell carcinoma of the penis. BJU International, 2015, 116, 734-743.	1.3	35
190	The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 29.e13-29.e20.	0.8	34
191	Asian Americans and prostate cancer: A nationwide population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 233.e7-233.e15.	0.8	34
192	Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. International Journal of Urology, 2017, 24, 743-748.	0.5	34
193	Quality Indicators for Bladder Cancer Services: A Collaborative Review. European Urology, 2020, 78, 43-59.	0.9	34
194	Radical Prostatectomy at Academic Versus Nonacademic Institutions: A Population Based Analysis. Journal of Urology, 2011, 186, 1849-1854.	0.2	33
195	Novel method of knotless vesicourethral anastomosis during robot-assisted radical prostatectomy: feasibility study and early outcomes in 30 patients using the interlocked barbed unidirectional V-LOC180 suture. Canadian Urological Association Journal, 2011, 5, 188-194.	0.3	33
196	Conditional survival after nephrectomy for renal cell carcinoma (<scp>RCC</scp>): changes in future survival probability over time. BJU International, 2013, 111, E283-9.	1.3	33
197	Contemporary Nationwide Patterns of Self-reported Prostate-Specific Antigen Screening. JAMA Internal Medicine, 2014, 174, 1839.	2.6	33
198	Care Transitions between Hospitals are Associated with Treatment Delay for Patients with Muscle Invasive Bladder Cancer. Journal of Urology, 2014, 192, 1349-1354.	0.2	33

#	Article	IF	CITATIONS
199	Evidence from the $\hat{a} \in PRO$ spective MulticEnTer Radlcal Cystectomy Series 2011 (PROMETRICS 2011) $\hat{a} \in PRO$ Study: How are Preoperative Patient Characteristics Associated with Urinary Diversion Type After Radical Cystectomy for Bladder Cancer?. Annals of Surgical Oncology, 2015, 22, 1032-1042.	0.7	33
200	Determinants of cancer screening in Asian-Americans. Cancer Causes and Control, 2016, 27, 989-998.	0.8	33
201	The Association between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer. Journal of Urology, 2018, 199, 424-429.	0.2	33
202	Analysis of Surgical Volume in Military Medical Treatment Facilities and Clinical Combat Readiness of US Military Surgeons. JAMA Surgery, 2022, 157, 43.	2.2	33
203	National trends in hospital-acquired preventable adverse events after major cancer surgery in the USA. BMJ Open, 2013, 3, e002843.	0.8	32
204	Partial and radical nephrectomy provide comparable longâ€term cancer control for <scp>T</scp> 1b renal cell carcinoma. International Journal of Urology, 2014, 21, 122-128.	0.5	32
205	Renal Pelvic Anatomy Is Associated with Incidence, Grade, and Need for Intervention for Urine Leak Following Partial Nephrectomy. European Urology, 2014, 66, 949-955.	0.9	32
206	Temporal Trends and Factors Associated with Systemic Therapy after Cytoreductive Nephrectomy: An Analysis of the National Cancer Database. Journal of Urology, 2015, 193, 1108-1113.	0.2	32
207	Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Medicine, 2016, 5, 192-199.	1.3	32
208	Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. Journal of Urology, 2016, 195, 913-918.	0.2	32
209	Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF Recommendations. JAMA Internal Medicine, 2016, 176, 546.	2.6	32
210	Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. European Journal of Surgical Oncology, 2018, 44, 1439-1445.	0.5	32
211	Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases. European Urology, 2019, 75, 352-353.	0.9	32
212	Is a Treatment Delay in Radical Prostatectomy Safe in Individuals with Lowâ€Risk Prostate Cancer?. Journal of Sexual Medicine, 2012, 9, 2961-2969.	0.3	31
213	Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU International, 2013, 112, E273-80.	1.3	31
214	Genderâ€specific effect of smoking on upper tract urothelial carcinoma outcomes. BJU International, 2013, 112, 623-637.	1.3	31
215	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 433-440.	0.8	31
216	Active Surveillance for Small Renal Masses: When Less is More. European Urology Focus, 2016, 2, 660-668.	1.6	31

#	Article	IF	Citations
217	A Surveillance, Epidemiology and End Results (<scp>SEER</scp>) database malfunction: perceptions, pitfalls and verities. BJU International, 2016, 117, 551-552.	1.3	31
218	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. Journal of Urology, 2017, 198, 1061-1068.	0.2	31
219	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology, 2018, 200, 573-581.	0.2	31
220	Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. European Urology Focus, 2021, 7, 124-131.	1.6	31
221	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. Journal of Urology, 2019, 201, 735-741.	0.2	31
222	Platelet Count and Preoperative Haemoglobin Do Not Significantly Increase the Performance of Established Predictors of Renal Cell Carcinoma-Specific Mortality. European Urology, 2007, 52, 1428-1437.	0.9	30
223	Associations of specific postoperative complications with costs after radical cystectomy. BJU International, 2018, 121, 428-436.	1.3	30
224	Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. European Urology, 2014, 66, 1125-1132.	0.9	29
225	Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU International, 2015, 116, 351-357.	1.3	29
226	Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort. Urology, 2016, 95, 88-94.	0.5	29
227	Nodeâ€positive renal cell carcinoma in the absence of distant metastases: predictors of cancerâ€specific mortality in a populationâ€based cohort. BJU International, 2012, 110, E21-7.	1.3	28
228	Inâ€hospital mortality and failureâ€toâ€rescue rates after radical cystectomy. BJU International, 2013, 112, E20-7.	1.3	28
229	Predictors of admission in patients presenting to the emergency department with urinary tract infection. World Journal of Urology, 2014, 32, 813-819.	1.2	28
230	The influence of physician recommendation on prostate-specific antigen screening. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 424.e1-424.e7.	0.8	28
231	Sepsis after major cancer surgery. Journal of Surgical Research, 2015, 193, 788-794.	0.8	28
232	Assessment of energy density usage during 180W lithium triborate laser photoselective vaporization of the prostate for benign prostatic hyperplasia. Is there an optimum amount of kiloâ€Joules per gram of prostate?. BJU International, 2016, 118, 633-640.	1.3	28
233	Prostate Cancer Screening in Early Medicaid Expansion States. Journal of Urology, 2018, 199, 81-88.	0.2	28
234	Adjuvant and Neoadjuvant Therapies in High-Risk Renal Cell Carcinoma. Hematology/Oncology Clinics of North America, 2011, 25, 765-791.	0.9	27

#	Article	IF	CITATIONS
235	Association of type of renal surgery and access to robotic technology for kidney cancer: results from a populationâ€based cohort. BJU International, 2014, 114, 549-554.	1.3	27
236	Anatomic Complexity Quantitated by Nephrometry Score Is Associated With Prolonged Warm Ischemia Time During Robotic Partial Nephrectomy. Urology, 2014, 84, 340-344.	0.5	27
237	National sociodemographic disparities in the treatment of highâ€risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. Cancer, 2016, 122, 3371-3377.	2.0	27
238	An Evaluation of the Timing of Surgical Complications Following Radical Cystectomy: Data From the American College of Surgeons National Surgical Quality Improvement Program. Urology, 2017, 103, 91-98.	0.5	27
239	Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men. BJU International, 2018, 121, 811-818.	1.3	27
240	Value-Based Healthcare in Urology: A Collaborative Review. European Urology, 2021, 79, 571-585.	0.9	27
241	Oncological and Functional Outcomes After Robot-assisted Radical Cystectomy: Critical Review of Current Status. Urology, 2011, 78, 977-984.	0.5	26
242	Clinical Characteristics Associated With Treatment Type for Localized Renal Tumors: Implications for Practice Pattern Assessment. Urology, 2013, 81, 269-276.	0.5	26
243	Internal Validation of the Renal Pelvic Score: A Novel Marker of Renal Pelvic Anatomy That Predicts Urine Leak After Partial Nephrectomy. Urology, 2014, 84, 351-357.	0.5	26
244	Laparoscopic Radical Nephrectomy vs Laparoscopic or Open Partial Nephrectomy for T1 Renal Cell Carcinoma: Comparison of Complication Rates in Elderly Patients During the Initial Phase of Adoption. Urology, 2014, 83, 1285-1293.	0.5	26
245	Is anatomic complexity associated with renal tumor growth kinetics under active surveillance?. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 167.e7-167.e12.	0.8	26
246	An evaluation of the timing of surgical complications following nephrectomy: data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). World Journal of Urology, 2015, 33, 2031-2038.	1.2	26
247	Access denied: The relationship between patient insurance status and access to highâ€volume hospitals. Cancer, 2021, 127, 577-585.	2.0	26
248	ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival. European Journal of Cancer, 2007, 43, 1023-1029.	1.3	25
249	Tablet Telerounding. Urology, 2012, 80, 1383-1388.	0.5	25
250	Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States. Cancer, 2012, 118, 1894-1900.	2.0	25
251	A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 46.e1-46.e7.	0.8	25
252	Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19. Annals of Surgical Oncology, 2021, 28, 8688-8696.	0.7	25

#	Article	IF	Citations
253	Health careâ€associated infections after major cancer surgery. Cancer, 2013, 119, 2317-2324.	2.0	24
254	Risk factors for biochemical recurrence following radical perineal prostatectomy in a large contemporary series: A detailed assessment of margin extent and location. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1470-1476.	0.8	24
255	Robot-assisted vs. Laparoscopic Partial Nephrectomy: utilization rates and perioperative outcomes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2013, 39, 377-386.	0.7	24
256	Minimally Invasive vs Open Pyeloplasty in Children: The Differential Effect of Procedure Volume on Operative Outcomes. Urology, 2014, 84, 180-184.	0.5	24
257	Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 27.e7-27.e13.	0.8	24
258	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 17.e9-17.e18.	0.8	24
259	National treatment trends among older patients with T1-localized renal cell carcinoma11Dr. Simon P. Kim is supported by a career development award from the Conquer Cancer Foundation from the American Society of Clinical Oncology Urologic Oncology: Seminars and Original Investigations, 2017, 35, 113.e15-113.e21.	0.8	24
260	Differences in Survival Associated with Performance of Lymph Node Dissection inÂPatients with Invasive Penile Cancer: Results from the National Cancer Database. Journal of Urology, 2018, 199, 1238-1244.	0.2	24
261	Trends in Surgical Volume in the Military Health System—A Potential Threat to Mission Readiness. Military Medicine, 2021, 186, 646-650.	0.4	24
262	Readmissions after major urologic cancer surgery. Canadian Journal of Urology, 2014, 21, 7537-46.	0.0	24
263	Sociodemographic disparities in the treatment of small renal masses. BJU International, 2013, 111, E274-82.	1.3	23
264	A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database. Journal of Endourology, 2015, 29, 1052-1058.	1.1	23
265	Wound dehiscence in a sample of 1Â776 cystectomies: identification of predictors and implications for outcomes. BJU International, 2016, 117, E95-E101.	1.3	23
266	Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. JAMA Network Open, 2019, 2, e194634.	2.8	23
267	Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. Cancer Cell, 2021, 39, 1042-1044.	7.7	23
268	Plasminogen Activation Inhibitor-1 Improves the Predictive Accuracy of Prostate Cancer Nomograms. Journal of Urology, 2007, 178, 1229-1237.	0.2	22
269	Discharge patterns after radical prostatectomy in the United States of America. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1022-1032.	0.8	22
270	Nodal involvement at nephrectomy is associated with worse survival: A stage-for-stage and grade-for-grade analysis. International Journal of Urology, 2013, 20, 372-380.	0.5	22

#	Article	IF	CITATIONS
271	Contemporary Volume–Outcome Relationships for Percutaneous Nephrolithotomy: Results from the Nationwide Inpatient Sample. Journal of Endourology, 2013, 27, 1107-1113.	1.1	22
272	Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis. BJU International, 2014, 113, 733-740.	1.3	22
273	Populationâ€based determinants of radical prostatectomy operative time. BJU International, 2014, 113, E112-8.	1.3	22
274	Early radiotherapy after radical prostatectomy improves cancerâ€specific survival only in patients with highly aggressive prostate cancer: Validation of recently released criteria. International Journal of Urology, 2015, 22, 89-95.	0.5	22
275	Adjuvant cisplatinâ€based combined chemotherapy for lymph node (<scp>LN</scp>)â€positive urothelial carcinoma of the bladder (<scp>UCB</scp>) after radical cystectomy (<scp>RC</scp>): a retrospective international study of >1500 patients. BJU International, 2015, 115, 722-727.	1.3	22
276	Doseâ€dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU International, 2016, 118, 221-229.	1.3	22
277	Racial differences in prostate-specific antigen–based prostate cancer screening: State-by-state and region-by-region analyses. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 460.e9-460.e20.	0.8	22
278	Racial Disparities in Treatment for Rectal Cancer at Minority-Serving Hospitals. Journal of Gastrointestinal Surgery, 2021, 25, 1847-1856.	0.9	22
279	Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. Journal of Geriatric Oncology, 2014, 5, 352-358.	0.5	21
280	Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?. American Journal of Medicine, 2015, 128, 609-616.	0.6	21
281	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. Urology, 2015, 85, 343-350.	0.5	21
282	The Impact of Resident Involvement in Male One-stage Anterior Urethroplasties. Urology, 2015, 85, 937-941.	0.5	21
283	Novel biomarkers of acute kidney injury: Evaluation and evidence in urologic surgery. World Journal of Nephrology, 2015, 4, 160.	0.8	21
284	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 504.e9-504.e17.	0.8	21
285	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e7-238.e17.	0.8	21
286	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1049-1058.	2.3	21
287	A Population-Based Analysis of Temporal Perioperative Complication Rates After Minimally Invasive Radical Prostatectomy. European Urology, 2011, 60, 564-571.	0.9	20
288	Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competingâ€risks analysis. BJU International, 2014, 114, E62-E69.	1.3	20

#	Article	IF	CITATIONS
289	Reassessing the value of highâ€volume cancer care in the era of precision medicine. Cancer, 2018, 124, 1319-1321.	2.0	20
290	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. European Urology, 2018, 73, 262-270.	0.9	20
291	Trends in Breast, Colorectal, and Cervical Cancer Incidence Following the Affordable Care Act. JAMA Oncology, 2018, 4, 128.	3.4	20
292	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Annals of Surgical Oncology, 2019, 26, 297-305.	0.7	20
293	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome raceâ€based differences in survival?. Cancer, 2019, 125, 1319-1329.	2.0	20
294	Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. European Urology Oncology, 2021, 4, 66-72.	2.6	20
295	Higher perioperative morbidity and inâ€hospital mortality in patients with endâ€stage renal disease undergoing nephrectomy for nonâ€metastatic kidney cancer: a populationâ€based analysis. BJU International, 2012, 110, E183-90.	1.3	19
296	The Health Care Burden of Skeletal Related Events in Patients with Renal Cell Carcinoma and Bone Metastasis. Journal of Urology, 2014, 191, 1678-1684.	0.2	19
297	The impact of Medicare eligibility on cancer screening behaviors. Preventive Medicine, 2016, 85, 47-52.	1.6	19
298	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. , 2019, 7, 289.		19
299	The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65Âyears. Cancer, 2020, 126, 496-505.	2.0	19
300	Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 163-167.	0.6	19
301	Impact of health literacy on shared decision making for prostateâ€specific antigen screening in the United States. Cancer, 2021, 127, 249-256.	2.0	19
302	Blood Transfusions in Radical Prostatectomy: A Contemporary Population-based Analysis. Urology, 2012, 79, 332-338.	0.5	18
303	Effect of Nodal Metastases on Cancer-specific Mortality After Cytoreductive Nephrectomy. Annals of Surgical Oncology, 2013, 20, 2096-2102.	0.7	18
304	Construction of predictive models for recurrence and progression in >1000 patients with nonâ€muscleâ€nvasive bladder cancer (<scp>NMIBC</scp>) from a single centre. BJU International, 2013, 111, E331-41.	1.3	18
305	Urolithiasis and Urinary Tract Infection Among Patients With Inflammatory Bowel Disease: A Review of US Emergency Department Visits between 2006 and 2009. Urology, 2015, 85, 764-770.	0.5	18
306	Variation in performance of candidate surgical quality measures for muscleâ€invasive bladder cancer by hospital type. BJU International, 2015, 115, 230-237.	1.3	18

#	Article	IF	Citations
307	Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort. Urology, 2016, 90, 69-75.	0.5	18
308	Accountable care organizations and the use of cancer screening. Preventive Medicine, 2017, 101, 15-17.	1.6	18
309	Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clinical Genitourinary Cancer, 2017, 15, e337-e343.	0.9	18
310	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node–Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score–Weighted Competing Risks Analysis. European Urology Focus, 2018, 4, 252-259.	1.6	18
311	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9–10 Prostate Cancer. European Urology, 2019, 75, 35-41.	0.9	18
312	Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group—American College of Radiology Imaging Network E2805 Trial Cohort. European Urology, 2020, 77, 277-281.	0.9	18
313	Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults. JAMA Network Open, 2020, 3, e1919185.	2.8	18
314	Prostate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups. JCO Oncology Practice, 2022, 18, e204-e218.	1.4	18
315	Leapfrog volume thresholds and perioperative complications after radical prostatectomy. Cancer, 2012, 118, 4991-4998.	2.0	17
316	Pediatric Nephrectomy: Incidence, Indications and Use of Minimally Invasive Techniques. Journal of Urology, 2014, 191, 764-770.	0.2	17
317	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. Urology, 2014, 83, 1316-1321.	0.5	17
318	The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1351-1358.	2.3	17
319	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e15-57.e22.	0.8	17
320	Variation in Locoregional Prostate Cancer Care and Treatment Trends at Commission on Cancer Designated Facilities: A National Cancer Data Base Analysis 2004 to 2013. Clinical Genitourinary Cancer, 2017, 15, e955-e968.	0.9	17
321	External Validation of Contact Surface Area as a Predictor of Postoperative Renal Function in Patients Undergoing Partial Nephrectomy. Journal of Urology, 2018, 199, 649-654.	0.2	17
322	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e129-e139.	0.9	17
323	Examining the relationship between complications and perioperative mortality following radical cystectomy: a populationâ€based analysis. BJU International, 2019, 124, 40-46.	1.3	17
324	Renal Hilar Lesions: Biological Implications for Complex Partial Nephrectomy. Urology, 2019, 123, 174-180.	0.5	17

#	Article	IF	CITATIONS
325	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 410-418.	2.0	17
326	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. World Journal of Urology, 2012, 30, 807-814.	1.2	16
327	Factors predicting prolonged operative time for individual surgical steps of robot-assisted radical prostatectomy (RARP): A single surgeon's experience. Canadian Urological Association Journal, 2015, 9, 417.	0.3	16
328	Effect of Preoperative Angina Pectoris on Cardiac Outcomes in Patients With Previous Myocardial Infarction Undergoing Major Noncardiac Surgery (Data from ACS-NSQIP). American Journal of Cardiology, 2015, 115, 1080-1084.	0.7	16
329	Comparison of 30-day perioperative outcomes in adults undergoing open versus minimally invasive pyeloplasty for ureteropelvic junction obstruction: analysis of 593 patients in a prospective national database. World Journal of Urology, 2015, 33, 2107-2113.	1.2	16
330	Bladder Preservation Therapy: A Review of the Literature and Future Directions. Urology, 2016, 96, 54-61.	0.5	16
331	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. Urology, 2016, 87, 125-132.	0.5	16
332	Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 670.e15-670.e21.	0.8	16
333	Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 78.e13-78.e19.	0.8	16
334	Cardiovascular toxicities associated with abiraterone compared to enzalutamide–A pharmacovigilance study. EClinicalMedicine, 2021, 36, 100887.	3.2	16
335	Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study. Canadian Urological Association Journal, 2012, 6, 245-250.	0.3	16
336	Venous thromboembolism after radical prostatectomy: the effect of surgical caseload. BJU International, 2012, 110, 828-833.	1.3	15
337	Incidence and Treatment Patterns in Males Presenting with Lower Urinary Tract Symptoms to the Emergency Department in the United States. Journal of Urology, 2013, 190, 1798-1804.	0.2	15
338	Delay in Nephrectomy and Cancer Control Outcomes in Elderly Patients with Small Renal Masses. Urologia Internationalis, 2014, 92, 455-461.	0.6	15
339	Active Surveillance for the Small Renal Mass. Urologic Clinics of North America, 2017, 44, 213-222.	0.8	15
340	Adoption of Technology and Its Impact on Nephrectomy Outcomes, a U.S. Population-Based Analysis (2008–2012). Journal of Endourology, 2017, 31, 91-99.	1.1	15
341	Postoperative sepsis prediction in patients undergoing major cancer surgery. Journal of Surgical Research, 2017, 209, 60-69.	0.8	15
342	Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. European Urology Focus, 2018, 4, 68-74.	1.6	15

#	Article	IF	CITATIONS
343	Cost-effectiveness of Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in the UK. JAMA Network Open, 2022, 5, e225740.	2.8	15
344	Potential role of 124l-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics: Targets and Therapy, 2012, 6, 395.	3.0	14
345	Open radical prostatectomy in the elderly: a case for concern?. BJU International, 2012, 109, 1335-1340.	1.3	14
346	Chronic kidney disease and perioperative outcomes in urological oncological surgery. International Journal of Urology, 2014, 21, 1245-1252.	0.5	14
347	Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample. World Journal of Urology, 2014, 32, 1511-1521.	1.2	14
348	Association between very small tumour size and increased cancerâ€specific mortality after radical prostatectomy in lymph nodeâ€positive prostate cancer. BJU International, 2016, 118, 279-285.	1.3	14
349	The Effect of Physician Specialty Obtaining Access for Percutaneous Nephrolithotomy on Perioperative Costs and Outcomes. Journal of Endourology, 2017, 31, 1152-1156.	1.1	14
350	Perioperative Outcomes Following Partial Nephrectomy Performed on Patients Remaining on Antiplatelet Therapy. Journal of Urology, 2017, 197, 31-36.	0.2	14
351	Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic. JAMA Oncology, 2021, 7, 1467.	3.4	14
352	Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability Study. JMIR MHealth and UHealth, 2020, 8, e20224.	1.8	14
353	Surgery for high-risk localized prostate cancer. Therapeutic Advances in Urology, 2011, 3, 173-182.	0.9	13
354	Balancing Process and Risk: Standardizing Posttreatment Surveillance for Renal Cell Carcinoma. Journal of Urology, 2013, 190, 417-418.	0.2	13
355	Patients with anatomically "simple―renal masses are more likely to be placed on active surveillance than those with anatomically "complex―lesions. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1267-1271.	0.8	13
356	Focal Therapy for Treatment of the Small Renal Mass: Dealer's Choice or a Therapeutic Gamble?. European Urology, 2015, 67, 260-261.	0.9	13
357	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy, 2016, 15, 695-700.	0.2	13
358	Adverse Event Rates, Timing of Complications, and the Impact of Specialty on Outcomes Following Adrenal Surgery: An Analysis of 30-Day Outcome Data From the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). Urology, 2016, 90, 62-68.	0.5	13
359	Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: Results from a population-based cohort. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 662.e17-662.e21.	0.8	13
360	Perioperative outcomes after radical cystectomy at NCI-designated centres: Are they any better?. Canadian Urological Association Journal, 2015, 9, 207.	0.3	13

#	Article	IF	CITATIONS
361	Active surveillance: a potential strategy for select patients with small renal masses. Future Oncology, 2011, 7, 1133-1147.	1.1	12
362	Annual Prostatectomy Volume Is Related to Rectal Laceration Rate After Radical Prostatectomy. Urology, 2012, 79, 796-803.	0.5	12
363	Utilization and perioperative outcomes of robotic vaginal vault suspension compared to abdominal or vaginal approaches for pelvic organ prolapse. Canadian Urological Association Journal, 2014, 8, 100.	0.3	12
364	Is Extended Pharmacologic Venous Thromboembolism Prophylaxis Uniformly Safe After Radical Cystectomy?. Urology, 2014, 84, 1152-1156.	0.5	12
365	Open Versus Robotic Radical Prostatectomy in Obese Men. Current Urology, 2015, 8, 156-161.	0.4	12
366	Pneumonia after Major Cancer Surgery: Temporal Trends and Patterns of Care. Canadian Respiratory Journal, 2016, 2016, 1-7.	0.8	12
367	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World Journal of Urology, 2018, 36, 1767-1774.	1.2	12
368	Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World Journal of Urology, 2020, 38, 2227-2236.	1.2	12
369	Ambulatory-Based Bladder Outlet Procedures Offer Significant Cost Savings and Comparable 30-Day Outcomes Relative to Inpatient Procedures. Journal of Endourology, 2020, 34, 1248-1254.	1.1	12
370	Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. Cancer, 2021, 127, 2714-2723.	2.0	12
371	Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses. European Journal of Surgical Oncology, 2022, 48, 687-693.	0.5	12
372	Conditional survival of patients with metastatic renal-cell carcinoma. Lancet Oncology, The, 2012, 13, e462.	5.1	11
373	The effect of insurance status on outcomes after partial nephrectomy. International Urology and Nephrology, 2012, 44, 343-351.	0.6	11
374	Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram. BJU International, 2015, 116, 703-712.	1.3	11
375	Preventable mortality after common urological surgery: failing to rescue?. BJU International, 2015, 115, 666-674.	1.3	11
376	Could lead-time bias explain the apparent benefits of early salvage radiotherapy?. Nature Reviews Urology, 2017, 14, 193-194.	1.9	11
377	Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 116-121.	0.9	11
378	Use of Preventive Health Services Among Cancer Survivors in the U.S American Journal of Preventive Medicine, 2018, 55, 830-838.	1.6	11

#	Article	IF	CITATIONS
379	Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e1060-e1068.	0.9	11
380	Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clinical Genitourinary Cancer, 2019, 17, e488-e493.	0.9	11
381	Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer. European Urology Oncology, 2020, 3, 104-111.	2.6	11
382	Lower odds of cardiac events for gonadotrophinâ€releasing hormone antagonists versus agonists. BJU International, 2020, 126, 9-10.	1.3	11
383	Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. JCO Oncology Practice, 2021, 17, e654-e665.	1.4	11
384	Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pTO Bladder Cancer: A Prospective Trial. Journal of Urology, 2021, 205, 1605-1611.	0.2	11
385	Sunitinib Relieves Renal Cell Carcinoma Spinal Cord Compression. European Urology, 2007, 51, 1741-1743.	0.9	10
386	Training and outcome monitoring in robotic urologic surgery. Nature Reviews Urology, 2012, 9, 17-22.	1.9	10
387	FG has no added value in prediction of mortality after partial and radical nephrectomy for chromophobe renal cell carcinoma patients. Modern Pathology, 2013, 26, 1144-1149.	2.9	10
388	Percutaneous suprapubic tube bladder drainage after robot-assisted radical prostatectomy: a step-by-step guide. BJU International, 2013, 112, 703-705.	1.3	10
389	Local tumor destruction in renal cell carcinoma—An inpatient population-based study. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 54.e1-54.e7.	0.8	10
390	The Effect of Resident Involvement on Surgical Outcomes for Common Urologic Procedures: A Case Study of Uni- and Bilateral Hydrocele Repair. Urology, 2016, 94, 70-76.	0.5	10
391	Accurately determining patients who underwent robotâ€assisted surgery: limitations of administrative databases. BJU International, 2016, 118, 346-348.	1.3	10
392	Relationship between androgen deprivation therapy and communityâ€acquired respiratory infections in patients with prostate cancer. International Journal of Urology, 2016, 23, 305-311.	0.5	10
393	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 421-428.	2.3	10
394	Weighing the evidence from surgical trials. BJU International, 2017, 119, 659-660.	1.3	10
395	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. Journal of Urology, 2017, 198, 1295-1300.	0.2	10
396	Understanding the impact and challenges of secondary data analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 163-164.	0.8	10

#	Article	IF	CITATIONS
397	Trends in Regionalization of Care and Mortality For Patients Treated With Radical Cystectomy. Medical Care, 2019, 57, 728-733.	1.1	10
398	The impact of smoking on radical cystectomy complications increases in elderly patients. Cancer, 2021, 127, 1387-1394.	2.0	10
399	Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?. Journal of Urology, 2021, 205, 1263-1274.	0.2	10
400	Accuracy of Transrectal Ultrasonography toÂEvaluate Pathologic Prostate Weight: Correlation With Various Prostate Size Groups. Urology, 2014, 84, 169-174.	0.5	9
401	Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 503.e7-503.e15.	0.8	9
402	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 338-343.	0.4	9
403	Testing the external validity of the EORTC randomized trial 30904 comparing overall survival after radical nephrectomy vs nephronâ€sparing surgery in contemporary North American patients with renal cell cancer. BJU International, 2018, 121, 345-347.	1.3	9
404	Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?. Urology, 2021, 147, 199-204.	0.5	9
405	Disparities in Outcomes following Admission for Cholangitis. PLoS ONE, 2013, 8, e59487.	1.1	9
406	Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International Consortium. Minerva Urology and Nephrology, 2022, 74, 186-193.	1.3	9
407	Robotic radical prostatectomy: a critical analysis of surgical quality. Current Opinion in Urology, 2011, 21, 195-199.	0.9	8
408	Urological resident exposure to transurethral surgical options for BPH management in 2012-2013: A pan-Canadian survey. Canadian Urological Association Journal, 2014, 8, 54.	0.3	8
409	An evaluation of the â€~weekend effect' in patients admitted with metastatic prostate cancer. BJU International, 2015, 116, 911-919.	1.3	8
410	Contemporary Trends in the Utilization of Radiotherapy in Patients With Renal Cell Carcinoma. Urology, 2015, 86, 1165-1173.	0.5	8
411	The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. Journal of Urology, 2016, 195, 399-405.	0.2	8
412	Race and postoperative complications following urologic cancer surgery: An ACS-NSQIP analysis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 670.e1-670.e6.	0.8	8
413	Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. Journal of Oncology Practice, 2019, 15, e547-e559.	2.5	8
414	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. Prostate Cancer and Prostatic Diseases, 2019, 22, 593-599.	2.0	8

#	Article	lF	CITATIONS
415	Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Survey. European Urology Focus, 2020, 6, 273-279.	1.6	8
416	Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. European Urology Focus, 2020, 6, 74-80.	1.6	8
417	Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 413-418.	0.6	8
418	Measuring What Matters: Patient-Reported Outcome and Experience Measures for Men Undergoing Radical Prostatectomy. European Urology Focus, 2021, 7, 913-915.	1.6	8
419	Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: A pharmacovigilance analysis of VigiBase. Journal of the American Academy of Dermatology, 2023, 88, 179-181.	0.6	8
420	Digital technologies in cancer care: a review from the clinician's perspective. Journal of Comparative Effectiveness Research, 2022, , .	0.6	8
421	Does partial nephrectomy at an academic institution result in better outcomes?. World Journal of Urology, 2012, 30, 505-510.	1.2	7
422	The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy. International Urology and Nephrology, 2012, 44, 799-806.	0.6	7
423	The Kubler-Ross model, physician distress, and performance reporting. Nature Reviews Urology, 2013, 10, 425-428.	1.9	7
424	NATIONAL RATES AND RISK FACTORS FOR STENT FAILURE IN PATIENTS WITH OBSTRUCTED, INFECTED UPPER TRACT STONES. Canadian Urological Association Journal, 2015, 9, 164.	0.3	7
425	A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report From the ClinicalTrials.gov WebSite. Clinical Genitourinary Cancer, 2015, 13, 142-149.	0.9	7
426	Understanding Chronic Kidney Disease of Surgical Versus Medical Origin: The Missing Link to the Partial Versus Radical Nephrectomy Debate?. European Urology, 2015, 68, 1004-1006.	0.9	7
427	Treatment patterns, testicular loss and disparities in inpatient surgical management of testicular torsion in boys: a populationâ€based study 1998–2010. BJU International, 2016, 118, 969-979.	1.3	7
428	Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. European Urology Focus, 2016, 2, 3-9.	1.6	7
429	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 563-569.e3.	0.9	7
430	State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update. Urology, 2018, 112, 56-65.	0.5	7
431	Contemporary trends in the utilisation of radical prostatectomy. BJU International, 2018, 122, 726-728.	1.3	7
432	Racial/ethnicity differences in endorsing influential factors for prostate cancer treatment choice: An analysis of data from the personal patient profile-prostate (P3P) I and II trials. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 78.e7-78.e13.	0.8	7

#	Article	IF	Citations
433	Association of Affordable Care Act-related Medicaid expansion with variation in utilization of surgical services. American Journal of Surgery, 2020, 220, 441-447.	0.9	7
434	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2020, 18, e651-e659.	0.9	7
435	Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. Lung, 2021, 199, 199-211.	1.4	7
436	Comparison of comorbidity indices for prediction of morbidity and mortality after major surgical procedures. American Journal of Surgery, 2021, 222, 998-1004.	0.9	7
437	Is the current referral trend a threat to the Military Health System? Perioperative outcomes and costs after colorectal surgery in the Military Health System versus civilian facilities. Surgery, 2021, 170, 67-74.	1.0	7
438	Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit. European Urology Open Science, 2021, 33, 1-10.	0.2	7
439	Robot-assisted Radical Prostatectomy: Ready To Be Counted?. European Urology, 2012, 62, 16-18.	0.9	6
440	Models of Assessment of Comparative Outcomes of Robot-Assisted Surgery. Urologic Clinics of North America, 2014, 41, 597-606.	0.8	6
441	Association of Androgen Deprivation Therapy With Alzheimer's Disease: Unmeasured Confounders. Journal of Clinical Oncology, 2016, 34, 2801-2803.	0.8	6
442	Risk Assessment in Small Renal Masses. Urologic Clinics of North America, 2017, 44, 189-202.	0.8	6
443	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 542.e25-542.e32.	0.8	6
444	Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 904-911.	0.4	6
445	Impact of Baseline Characteristics on the Survival Benefit of High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder. European Urology Focus, 2018, 4, 568-571.	1.6	6
446	Costs variations for percutaneous nephrolithotomy in the U.S. from 2003–2015: A contemporary analysis of an all-payer discharge database. Canadian Urological Association Journal, 2018, 12, .	0.3	6
447	Testosterone replacement therapy is associated with an increased risk of urolithiasis. World Journal of Urology, 2019, 37, 2737-2746.	1.2	6
448	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. European Urology Oncology, 2019, 2, 349-354.	2.6	6
449	Comparison of testis cancerâ€specific survival: an analysis of national cancer registry data from the USA, UK and Germany. BJU International, 2019, 123, 385-387.	1.3	6
450	Minimally invasive cancer surgery is associated with a lower risk of venous thromboembolic events. Journal of Surgical Oncology, 2020, 121, 578-583.	0.8	6

#	Article	IF	CITATIONS
451	Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 74.e13-74.e20.	0.8	6
452	Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. Current Opinion in Urology, 2020, Publish Ahead of Print, 701-710.	0.9	6
453	Inequity in selective referral to high-volume hospitals for genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 582-589.	0.8	6
454	The Relationship Between Health Literacy and Nonrecommended Cancer Screening. American Journal of Preventive Medicine, 2021, 60, e69-e72.	1.6	6
455	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 85-95.	2.0	6
456	Association of abiraterone and higher odds of cardiac complications compared to enzalutamide Journal of Clinical Oncology, 2020, 38, 70-70.	0.8	6
457	Variations in the quality of care at radical prostatectomy. Therapeutic Advances in Urology, 2012, 4, 61-75.	0.9	5
458	Robot-assisted urological surgery: Current status and future perspectives. Arab Journal of Urology Arab Association of Urology, 2012, 10, 17-22.	0.7	5
459	Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States. JAMA Oncology, 2016, 2, 543.	3.4	5
460	Do micropapillary patients benefit from chemotherapy?. BJU International, 2017, 119, 656-658.	1.3	5
461	Assessing robot-assisted laparoscopic prostatectomy. Lancet, The, 2017, 389, 799.	6.3	5
462	The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 575.e9-575.e18.	0.8	5
463	Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy. Urology, 2020, 135, 44-49.	0.5	5
464	Temporal Trends in the Incidence of Testicular Cancer in the United States over the Past Four Decades. European Urology Oncology, 2021, 4, 834-836.	2.6	5
465	Accounting for Readiness—Integrating Time-Driven Activity-Based Costing (TDABC) into the Military Health System. Military Medicine, 2020, 185, e930-e933.	0.4	5
466	Prostate cancer and kidney transplantation – exclusion or coâ€existence?. BJU International, 2020, 125, 628-629.	1.3	5
467	Identification of oncological characteristics associated with improved overall survival in patients with adrenocortical carcinoma treated with adjuvant radiation therapy: Insights from the National Cancer Database. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 791.e1-791.e7.	0.8	5
468	The effect of gender on nephrectomy perioperative outcomes: a national survey. Canadian Journal of Urology, 2012, 19, 6337-44.	0.0	5

#	Article	IF	Citations
469	The current management of small renal masses. Current Opinion in Supportive and Palliative Care, 2009, 3, 180-185.	0.5	4
470	Molecular imaging of the small renal mass. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 589-592.	0.8	4
471	Adoption of Robotic Surgery: An Analogy From Urologic Oncology. Journal of Clinical Oncology, 2012, 30, 2931-2932.	0.8	4
472	Are Medicare-Based Findings Applicable to All Prostatectomy Patients?. Journal of Clinical Oncology, 2012, 30, 2286-2287.	0.8	4
473	Discharge Patterns After Radical Cystectomy: Contemporary Trends in the United States. Journal of Urology, 2012, 187, 1206-1209.	0.2	4
474	Data on Medicare eligibility and cancer screening utilization. Data in Brief, 2016, 7, 679-681.	0.5	4
475	The diminishing returns of robotic diffusion: complications after robotâ€essisted radical prostatectomy. BJU International, 2016, 117, 211-212.	1.3	4
476	Risk of Small Bowel Obstruction After Robot-Assisted <i>vs</i> Open Radical Prostatectomy. Journal of Endourology, 2016, 30, 1291-1295.	1.1	4
477	Trends in Prostate-Specific Antigen Screening Since the Implementation of the 2012 US Preventive Services Task Force Recommendations. European Urology Focus, 2018, 4, 1002-1004.	1.6	4
478	Does the Surgical Apgar Score predict serious complications after elective major cancer surgery?. Journal of Surgical Research, 2018, 231, 242-247.	0.8	4
479	A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World Journal of Urology, 2019, 37, 2099-2108.	1.2	4
480	Treatment delays for muscleâ€invasive bladder cancer. Cancer, 2019, 125, 1973-1975.	2.0	4
481	Clinical applications of artificial intelligence in urologic oncology. Current Opinion in Urology, 2020, 30, 748-753.	0.9	4
482	Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer?. Journal of Comparative Effectiveness Research, 2021, 10, 733-741.	0.6	4
483	Renal mass biopsy: A strategy to reduce associated costs and morbidity when managing localized renal masses. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 790.e9-790.e15.	0.8	4
484	Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 436.e1-436.e10.	0.8	4
485	Recovery from minimally invasive vs. open surgery in kidney cancer patients: Opioid use and workplace absenteeism. Investigative and Clinical Urology, 2021, 62, 56.	1.0	4
486	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. Journal of Urology, 2019, 201, 728-734.	0.2	4

#	Article	IF	CITATIONS
487	Combination of Tadalafil and Finasteride for the Treatment of Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Commercialization of the Prescribing Cascade. European Urology, 2022, 81, 323-324.	0.9	4
488	Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors ± androgen deprivation therapy: a pharmacovigilance study. Prostate Cancer and Prostatic Diseases, 2022, , .	2.0	4
489	Proof of Efficacy Is Not Enough: Contemporary Management of Patients With Metastatic Renal Cell Carcinoma With Targeted Therapy. Journal of Clinical Oncology, 2012, 30, 3901-3901.	0.8	3
490	1466 PREOPERATIVE NOMOGRAM PREDICTING ERECTILE FUNCTION TWO YEARS AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.2	3
491	1597 GENDER DIFFERENCES IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY A POPULATION-BASED ANALYSIS. Journal of Urology, 2012, 187, .	0.2	3
492	1634 MANAGEMENT OF LOCALIZED KIDNEY CANCER: CALCULATING CANCER-SPECIFIC MORTALITY AND COMPETING-RISKS OF DEATH TRADEOFFS BETWEEN SURGERY AND ACTIVE SURVEILLANCE. Journal of Urology, 2013, 189, .	0.2	3
493	Statistical Analysis Plans in Observational Research. JAMA - Journal of the American Medical Association, 2013, 309, 32.	3.8	3
494	Perceptions of Radiation Oncologists and Urologists onÂSources and Type of Evidence to Inform Prostate Cancer Treatment Decisions. International Journal of Radiation Oncology Biology Physics, 2014, 89, 277-283.	0.4	3
495	The Controversy That Will Not Go Away. European Urology, 2015, 67, 439-440.	0.9	3
496	MP39-14 IMPACT OF THE 2012 UNITED STATES PREVENTIVE SERVICES TASK FORCE RECOMMENDATION AGAINST PROSTATE SPECIFIC ANTIGEN SCREENING ON PROSTATE CANCER RISK GROUP STRATIFICATION. Journal of Urology, 2016, 195, .	0.2	3
497	Reply to Patrick O. Richard, Micheal A.S. Jewett and Antonio Finelli's Letter to the Editor re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Haifler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? Eur Urol 2016;70:403–6. European Urology, 2017, 71, e47-e48.	0.9	3
498	The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Therapeutic Advances in Urology, 2018, 10, 3-10.	0.9	3
499	What can the National Cancer Database tell us about disparities in advanced bladder cancer outcomes?. Translational Andrology and Urology, 2018, 7, 732-735.	0.6	3
500	Performance Measurement and Quality Improvement Initiatives for Bladder Cancer Care. Current Urology Reports, 2018, 19, 100.	1.0	3
501	Pathologic measures of quality compare favorably in patients undergoing robot-assisted radical cystectomy to open cystectomy cohorts: a National Cancer Database analysis. Journal of Robotic Surgery, 2020, 14, 609-614.	1.0	3
502	Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. Annals of Surgical Oncology, 2020, 27, 1929-1936.	0.7	3
503	Care Setting as a Modifiable Predictor of Perioperative Cost and Outcomes following Elective Urinary Stone Surgery. Urology Practice, 2020, 7, 259-265.	0.2	3
504	Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position. Cancer, 2021, 127, 2525-2534.	2.0	3

#	Article	IF	CITATIONS
505	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. International Journal of Clinical Oncology, 2021, 26, 1729-1735.	1.0	3
506	Impact of Accountable Care Organizations on Prostate Cancer Screening and Biopsies in the United States. Urology Practice, 2019, 6, 159-164.	0.2	3
507	1245: The Presence of Tumor Necrosis within the Primary Tumor Cannot Independently Predict Renal Cell Carcinoma-Specific Mortality after Nephrectomy. Journal of Urology, 2007, 177, 410-410.	0.2	3
508	Receipt of Survivorship Care Plans and Self-Reported Health Status among Patients with Genitourinary Malignancy. Journal of Urology, 2020, 204, 564-569.	0.2	3
509	Shared decision making for prostate cancer screening: Reality or farce?. Journal of Clinical Oncology, 2018, 36, 107-107.	0.8	3
510	Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study. Prostate Cancer and Prostatic Diseases, 2023, 26, 287-292.	2.0	3
511	Editorial Comment on: A Novel Approach to Energy Ablative Therapy of Small Renal Tumours: Laparoscopic High-Intensity Focused Ultrasound. European Urology, 2008, 53, 817-818.	0.9	2
512	Editorial Comment. Journal of Urology, 2011, 186, 1777-1778.	0.2	2
513	Objectifying risk for localized renal masses. Nature Reviews Urology, 2012, 9, 70-72.	1.9	2
514	1701 ACCURACY OF THE EORTC RISK TABLES AND OF THE CUETO SCORING MODEL TO PREDICT OUTCOMES IN NON MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER. Journal of Urology, 2013, 189, .	0.2	2
515	Reply to Hiten D. Patel and Mohamad E. Allaf's Letter to the Editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of Localized Kidney Cancer: Calculating Cancer-specific Mortality and Competing Risks of Death for Surgery and Nonsurgical Management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034. European Urology, 2013, 64, e107-e108.	0.9	2
516	Is a Minimally Invasive Approach the Solution for Reducing Surgical Site Infections?. JAMA Surgery, 2014, 149, 1044.	2.2	2
517	Reply to Vincenzo Ficarra, Vito Palumbo, Afrovita Rungulli and Gianiuca Giannarini's Letter to the Editor re: Andrea Minervini, Marco Carini, Robert G. Uzzo, Riccardo Campi, Marc C. Smaldone, Alexander Kutikov. Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface–Intermediate–Base Margin Score. Eur Urol 2014;66:803–5. European Urology, 2015, 67,	0.9	2
518	Complications After Surgery for Stress Urinary Incontinence. JAMA Surgery, 2015, 150, 1175.	2.2	2
519	Men's health supplement use and outcomes in men receiving definitive intensity-modulated radiation therapy for localized prostate cancer. American Journal of Clinical Nutrition, 2016, 104, 1583-1593.	2.2	2
520	Observational Studies to Contextualize Surgical Trials. European Urology, 2016, 70, 231-232.	0.9	2
521	Re: Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. European Urology, 2016, 69, 963-964.	0.9	2
522	New evidence from the Prostate Cancer Prevention Trial may exculpate cyclooxygenase (<scp>COX</scp>) blockers in erectile dysfunction. BJU International, 2016, 117, 385-386.	1.3	2

#	Article	IF	CITATIONS
523	30-Day Adverse Events Following Cystectomy for Bladder Cancer Versus Benign Bladder Conditions. Urology Practice, 2017, 4, 388-394.	0.2	2
524	Challenging Residual Contamination of Instruments for Robotic Surgery in Japan. Infection Control and Hospital Epidemiology, 2017, 38, 501-502.	1.0	2
525	The Small Renal Mass and Its Management in Urologic Practice. Urologic Clinics of North America, 2017, 44, xvii.	0.8	2
526	PD32-05 PROSTATE CANCER SCREENING: EFFECT OF EARLY MEDICAID EXPANSION. Journal of Urology, 2017, 197, .	0.2	2
527	Does Low-value Care Affect Urologists?. European Urology, 2017, 71, 304-305.	0.9	2
528	Adoption of robotic surgery: driven by market competition or a desire to improve patient care?. Lancet Oncology, The, 2018, 19, e66.	5.1	2
529	Challenges facing regionalization of radical cystectomy. Translational Andrology and Urology, 2018, 7, 292-294.	0.6	2
530	Melancholia and cancer: The bladder cancer narrative. Cancer, 2018, 124, 3080-3083.	2.0	2
531	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Canadian Urological Association Journal, 2018, 13, 32-37.	0.3	2
532	Multiparametric magnetic resonance imaging for prostate cancer detection: do clinical trial findings reflect realâ€world practice?. BJU International, 2019, 123, 197-198.	1.3	2
533	Suicide Risk Among Patients with Genitourinary Malignancies: Where Do We Stand?. European Urology Focus, 2020, 6, 1145-1146.	1.6	2
534	Association of surgical approach and prolonged opioid prescriptions in patients undergoing major pelvic cancer procedures. BMC Surgery, 2020, 20, 235.	0.6	2
535	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 735.e9-735.e15.	0.8	2
536	Prostate cancer management costs vary by disease stage at presentation. Prostate Cancer and Prostatic Diseases, 2020, 23, 564-566.	2.0	2
537	All for one, one for all: is centralisation the way to go?. BJU International, 2020, 125, 191-192.	1.3	2
538	Workplace absenteeism amongst patients undergoing open vs. robotic radical prostatectomy, hysterectomy, and partial colectomy. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 1644-1650.	1.3	2
539	Temporal trends in the incidence of distantâ€stage bladder cancer among young individuals. International Journal of Urology, 2021, 28, 704-705.	0.5	2
540	Association of Hair Loss With Suicidality and Psychological Adverse Events vs Finasteride Useâ€"Reply. JAMA Dermatology, 2021, 157, 738.	2.0	2

#	Article	IF	CITATIONS
541	Predicting survival after radical prostatectomy: Variation of machine learning performance by race. Prostate, 2021, 81, 1355-1364.	1.2	2
542	Limitations of using the National Cancer Database to examine the effect of policy change on stage at presentation at the population level. Journal of the American Academy of Dermatology, 2021, 85, e195-e196.	0.6	2
543	1246: Nephron-Sparing Surgery does not Undermine Renal Cell Carcinoma-Specific Survival in Patients with PT3 Renal Cell Carcinoma. Journal of Urology, 2007, 177, 411-411.	0.2	2
544	Health literacy is a barrier to shared decision making in early prostate cancer (PCA) among African American (AA) men Journal of Clinical Oncology, 2019, 37, 84-84.	0.8	2
545	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3091-3102.	1.2	2
546	Venous Thromboembolism in Colorectal Surgery: How Much Does Laparoscopy Impart an Advantage?. Archives of Surgery, 2012, 147, 199.	2.3	1
547	THE CASE FOR PARTIAL NEPHRECTOMY: ACTION IS REQUIRED. BJU International, 2012, 110, 1097-1098.	1.3	1
548	Causality in administrative datasets. Journal of Crohn's and Colitis, 2012, 6, 867.	0.6	1
549	Re: Complications after Prostate Biopsy: Data from SEER-Medicare. Journal of Urology, 2012, 188, 677-678.	0.2	1
550	Reply from Authors re: Brian R. Matlaga. How Do We Manage Infected, Obstructed Hydronephrosis? Eur Urol 2013;64:93–4. European Urology, 2013, 64, 95-96.	0.9	1
551	Re: Perioperative Outcomes and Oncologic Efficacy from a Pilot Prospective Randomized Clinical Trial of Open Versus Robotic Assisted Radical Cystectomy. Journal of Urology, 2013, 190, 811-812.	0.2	1
552	Robotic and conventional open radical cystectomy lead to similar postoperative healthâ€related quality of life. BJU International, 2014, 114, 793-794.	1.3	1
553	Measuring the Effectiveness of Androgen-Deprivation Therapy for Prostate Cancer in the Medicare Population. JAMA Internal Medicine, 2014, 174, 1468.	2.6	1
554	High hospital volume reduces mortality after cystectomy. BJU International, 2014, 114, 5-6.	1.3	1
555	Use of advanced treatment technologies among men at low risk of dying from prostate cancer. BJU International, 2014, 114, 166-167.	1.3	1
556	PD12-12 ADJUVANT RADIOTHERAPY IMPROVES CANCER-SPECIFIC SURVIVAL ONLY IN PATIENTS WITH HIGHLY AGGRESSIVE PROSTATE CANCER. VALIDATION OF RECENTLY RELEASED CRITERIA. Journal of Urology, 2014, 191, .	0.2	1
557	Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 525-530.	2.3	1
558	Prevalence and risk factors of contralateral extraprostatic extension in men undergoing radical prostatectomy for unilateral disease at biopsy: A global multi-institutional experience. Canadian Urological Association Journal, 2015, 9, 434.	0.3	1

#	Article	IF	CITATIONS
559	The need for standardised reporting of complications <scp>R</scp> e: Minimum 5â€years followâ€up of 1138 consecutive laparoscopic radical prostatectomies. BJU International, 2015, 115, 501-502.	1.3	1
560	A Nationwide Survey of Prostate Specific Antigen Based Screening and Counseling for Prostate Cancer. Urology Practice, 2017, 4, 210-217.	0.2	1
561	Emerging guidelines for managing small renal masses. Nature Reviews Urology, 2017, 14, 329-330.	1.9	1
562	Immortalâ€time bias: a crucial yet overlooked confounder in urological research. BJU International, 2017, 120, 455-455.	1.3	1
563	Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol 2017;72:488–9. European Urology, 2017, 72, 489-491.	0.9	1
564	Factors Influencing Prostate Specific Antigen Testing in the United States. Urology Practice, 2018, 5, 438-443.	0.2	1
565	Use of administrative data for comparative effectiveness research in the treatment of non-prostate genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 193-212.	0.8	1
566	Comparative Effectiveness of Transurethral Resection Techniques in the Inpatient Setting for Benign Prostatic Hyperplasia. Urology Practice, 2018, 5, 377-382.	0.2	1
567	Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018:73:262–70. European Urology, 2018. 73. e100-e101.	0.9	1
568	Perioperative Statin Use and Acute Kidney Injury in Patients Undergoing Partial Nephrectomy. Kidney Cancer, 2018, 2, 47-55.	0.2	1
569	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 400.e15-400.e22.	0.8	1
570	Bladder Extirpation vs Preservation. JAMA Surgery, 2018, 153, 889.	2.2	1
571	Machines in urology: a brief odyssey of the future. BJU International, 2019, 124, 545-546.	1.3	1
572	Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. Urology, 2020, 145, 197-203.	0.5	1
573	Real-world comparative effectiveness of shockwave lithotripsy versus ureterorenoscopy for the treatment of urinary stones. World Journal of Urology, 2021, 39, 2177-2182.	1.2	1
574	Delayed blood transfusion is associated with mortality following radical cystectomy. Scandinavian Journal of Urology, 2020, 54, 290-296.	0.6	1
575	Safety of neoadjuvant chemotherapy in patients with muscleâ€invasive bladder cancer and malignant ureteric obstruction. BJU International, 2021, , .	1.3	1
576	Association of the hospital readmission reduction program with readmission and mortality outcomes after coronary artery bypass graft surgery. Journal of Cardiac Surgery, 2021, 36, 3251-3258.	0.3	1

#	Article	IF	CITATIONS
577	High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 62.e1-62.e11.	0.8	1
578	MP41-09â€∱QUALITY OF CARE IN THE TREATMENT OF LOCALIZED INTERMEDIATE AND HIGH RISK PROSTATE CANCER AT MINORITY SERVING HOSPITALS. Journal of Urology, 2019, 201, .	0.2	1
579	Providers' inability to estimate health literacy among African American (AA) patients (pts) with early prostate cancer (PCa) Journal of Clinical Oncology, 2019, 37, 77-77.	0.8	1
580	Radical prostatectomy in metastatic prostate cancer: is there enough evidence? Opinion: No. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 880-882.	0.7	1
581	Understanding the roles of randomized trials for robotic prostatectomy. Annals of Translational Medicine, 2016, 4, 467-467.	0.7	1
582	Radical prostatectomy for high-risk prostate cancer Opinion: YES. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 424-427.	0.7	1
583	Reply by Authors. Journal of Urology, 2020, 203, 503-504.	0.2	1
584	Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted". Annals of Translational Medicine, 2015, 3, 274.	0.7	1
585	Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The) Tj ETQq1 1 0.784	43 1.⊕ rgBT	/ Q verlock 10
586	Hormone Treatment of Prostate Cancer:. Urologic Clinics of North America, 2022, 49, 309-321.	0.8	1
587	Sutent Relieves Renal Cell Carcinoma Spinal Cord Compression: Part II. European Urology, 2007, 52, 273-274.	0.9	0
588	V1882 ROBOT ASSISTED PROSTATE-SPARING RADICAL CYSTECTOMY. Journal of Urology, 2011, 185, .	0.2	0
589	Editorial Comment to Robotâ€assisted or pure laparoscopic nerveâ€sparing radical prostatectomy: What is the optimal procedure for the surgical margins? A single center experience. International Journal of Urology, 2012, 19, 1082-1082.	0.5	0
590	Reply to Gurdarshan S. Sandhu, Youssef S. Tanagho and Sam B. Bhayani's Letter to the Editor re: Maxine Sun, Quoc-Dien Trinh, Marco Bianchi, et al. A Non-Cancer-Related Survival Benefit Is Associated With Partial Nephrectomy. Eur Urol. 2012;61:725–31. European Urology, 2012, 62, e59-e60.	0.9	0
591	Re: Improved Prediction of Long-Term, Other Cause Mortality in Men With Prostate Cancer. Journal of Urology, 2012, 187, 1931-1931.	0.2	0
592	Re: A Double-Blind Randomized Controlled Clinical Trial to Assess the Effect of Doppler Optimized Intraoperative Fluid Management on Outcome Following Radical Cystectomy. Journal of Urology, 2012, 187, 2278-2279.	0.2	0
593	358 CREATION OF A PREOPERATIVE NOMOGRAM THAT INCLUDES ENDORECTAL MRI ACCURATELY PREDICTS NON ORGAN-CONFINED PROSTATE CANCER. Journal of Urology, 2012, 187, .	0.2	0
594	V405 ENUCLEATION TECHNIQUES FOR CHALLENGING ROBOT-ASSISTED PARTIAL NEPHRECTOMY CASES. Journal of Urology, 2012, 187, .	0.2	0

#	Article	IF	Citations
595	1390 PROSPECTIVE, RANDOMIZED USE OF THE VLOC VESICOURETHRAL ANASTAMOSIS DURING ROBOT ASSISTED RADICAL PROSTATECTOMY: LONG-TERM FOLLOWUP. Journal of Urology, 2012, 187, .	0.2	O
596	Tu1715 Biliary Drainage Method and Temporal Trends in Patients Admitted With Cholangitis: A National Audit. Gastrointestinal Endoscopy, 2012, 75, AB498.	0.5	0
597	V1027 ROBOT-ASSISTED SIMPLE PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.2	0
598	THE PHANTOM MENACE OF PROSTATE CANCER SCREENING. BJU International, 2012, 109, 324-326.	1.3	0
599	1635 BENEFIT IN REGIONALIZATION OF CARE FOR PATIENTS TREATED WITH NEPHRECTOMY: A NATIONWIDE INPATIENT SAMPLE. Journal of Urology, 2013, 189, .	0.2	0
600	Oncological vs functional outcomes for RARP—finding a balance. Nature Reviews Urology, 2013, 10, 563-564.	1.9	0
601	Re: Surgeon Variation in Patient Quality of Life after Radical Prostatectomy. Journal of Urology, 2013, 190, 1441-1442.	0.2	0
602	52 TOTAL AND PARTIAL ADRENALECTOMY HAVE SIMILAR PERI-OPERATIVE OUTCOMES. Journal of Urology, 2013, 189, .	0.2	0
603	Reply to Georgios Papadopoulos, Georgios Stathouros and Konstantinos Doumas' Letter to the Editor re: Maxine Sun, Marco Bianchi, Jens Hansen, et al. Chronic Kidney Disease After Nephrectomy in Patients with Small Renal Masses: A Retrospective Observational Analysis. Eur Urol 2012;62:696–703. European Urology. 2013. 63. e65-e66.	0.9	O
604	Prostate Cancer Screening and Incidence: A Question of Causality. JAMA Internal Medicine, 2013, 173, 392.	2.6	0
605	Editorial Comment. Urology, 2014, 83, 779.	0.5	0
606	PD7-06 NATIONAL RATES AND RISK FACTORS FOR STENT FAILURE IN PATIENTS WITH OBSTRUCTED, INFECTED UPPER TRACT STONES. Journal of Urology, 2014, 191, .	0.2	0
607	Predicting Other-cause Mortality: The Minimalistic Approach. European Urology, 2014, 66, 1010-1011.	0.9	0
608	Perioperative aspirin: To give or not to give?. BJU International, 2014, 114, 318-319.	1.3	0
609	Editorial Comment. Urology, 2014, 83, 630-631.	0.5	0
610	How can we improve surgical outcomes?. BJU International, 2015, 116, 835-836.	1.3	0
611	Reply. Urology, 2015, 85, 349-350.	0.5	0
612	MP37-02 INFORMED DECISION-MAKING FOR PROSTATE-SPECIFIC ANTIGEN SCREENING. Journal of Urology, 2016, 195, .	0.2	0

#	Article	IF	CITATIONS
613	Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Jesse D. Sammon, Firas Abdollah, Anthony D'Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol 2015;68:756–65. European Urology, 2016, 69, e129.	0.9	O
614	Editorial Comment. Journal of Urology, 2016, 196, 333-334.	0.2	0
615	MP21-07 THE AFFORDABLE CARE ACT AND PSA SCREENING PRACTICES: ANALYSIS OF RACIAL SUBGROUPS. Journal of Urology, 2016, 195, .	0.2	0
616	Editorial Comment. Urology, 2016, 95, 101-102.	0.5	0
617	MP25-08 DETERMINANTS OF PROSTATE CANCER SCREENING IN ASIAN AMERICANS. Journal of Urology, 2016, 195, .	0.2	O
618	Effects of Time to Treatment on Biochemical and Clinical Outcomes for Patients With Prostate Cancer Treated With Definitive Radiation. Clinical Genitourinary Cancer, 2016, 14, e463-e468.	0.9	0
619	Editorial Comment. Urology, 2016, 87, 86-87.	0.5	O
620	Role of collaboration between urologists and medical oncologists in the advanced prostate cancer space. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 665-669.	0.8	0
621	National utilization of regional lymph node dissection among patients with kidney cancer and clinical lymphadenopathy undergoing radical nephrectomy. Cancer Treatment and Research Communications, 2017, 12, 14-18.	0.7	O
622	PD05-11 CONTEMPORARY PERCEPTIONS OF HUMAN PAPILLOMAVIRUS AND PENILE CANCER – PERSPECTIVES FROM A NATIONAL SURVEY. Journal of Urology, 2017, 197, .	0.2	0
623	Reply to C. Buttigliero et al and B. Biswas et al. Journal of Clinical Oncology, 2017, 35, 1266-1267.	0.8	O
624	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262–70 European Urology, 2018, 73, e96-e97.	0.9	0
625	The new frontier of prostate biopsy: determining the role of imageâ€guidance in moving the needle. BJU International, 2018, 121, 4-5.	1.3	0
626	Editorial Comment. Journal of Urology, 2018, 199, 914-914.	0.2	0
627	Evaluation of magnetic resonance imaging and targeted biopsy: The difficulty of finding the right reference standard. Cancer, 2018, 124, 1299-1300.	2.0	O
628	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy. JAMA Oncology, 2018, 4, 1619.	3.4	0
629	Health Services Research and Robotic Surgery. , 2018, , 235-252.		O
630	EDITORIAL COMMENT. Urology, 2019, 130, 84-85.	0.5	0

#	ARTICLE	IF	CITATIONS
631	Reply to Amar U. Kishan, William Hall, and Daniel Spratt's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552–5 Comparing Apples to Oranges: A Self-fulfilling Prophecy?.	0.9	0
632	Trimodal Therapy for Bladder Cancer. JAMA Surgery, 2019, 154, e191637.	2.2	0
633	Reply to Michael Froehner and Christian Thomas's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019:75:552–5. European Urology. 2019. 76. e76-e77.	0.9	O
634	A New Era in Surgical Evaluation—What Is at Stake?. JAMA Surgery, 2021, 156, e206360.	2.2	0
635	Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly –An International Multicenter Study. Bladder Cancer, 2021, 7, 173-185.	0.2	0
636	Reply to: Axel Heidenreich. Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer. Eur Urol 2021;79:605–6. European Urology, 2021, 79, 607-608.	0.9	0
637	Francesco Montorsi's Letter to the Editor re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol 2021:79:595–604. Time for a Change? Clinically Meaningful Reasons Why We Will	0.9	0
638	Continue Performin, European Urology, 2021, 79, e184-e185. ASO Author Reflections: How We Convey Empathy, Address Uncertainty, and Share Serious News: Challenges to Remote Surgical Care. Annals of Surgical Oncology, 2021, 28, 8697-8698.	0.7	0
639	Research highlights of the 2020 society of urologic oncology young urologic oncologists' program. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 452-454.	0.8	0
640	1427: Circulating Levels of Plasminogen Activation Inhibitor-1 Improve the Accuracy of Pre- and Post-Operative Nomograms for Prediction of Prostate Cancer Recurrence after Radical Prostatectomy. Journal of Urology, 2007, 177, 471-471.	0.2	0
641	Robot-Assisted Partial Nephrectomy. Videourology (New Rochelle, N Y), 2011, 25, .	0.1	o
642	The Medical Necessity of Nephron-Sparing Surgery. International Journal of Clinical Reviews, 0, , .	0.1	0
643	Concerning Trends in the Management of Metastatic Pancreatic Cancer. American Journal of Gastroenterology, 2013, 108, S89.	0.2	0
644	The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer Journal of Clinical Oncology, 2014, 32, 5091-5091.	0.8	0
645	Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database Journal of Clinical Oncology, 2015, 33, 34-34.	0.8	0
646	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer Journal of Clinical Oncology, 2016, 34, 54-54.	0.8	0
647	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer Journal of Clinical Oncology, 2018, 36, 78-78.	0.8	0
648	Do accountable care organizations impact prostate cancer screening?. Journal of Clinical Oncology, 2018, 36, 6546-6546.	0.8	0

Quoc-Dien Trinh

#	Article	IF	CITATIONS
649	Editorial Comment. Journal of Urology, 2018, 200, 987-988.	0.2	O
650	Response to Loughlin re: "Ambulatory-Based Bladder Outlet Procedures Offer Significant Cost Savings and Comparable 30-Day Outcomes Relative to Inpatient Surgery―by Nguyen et al Journal of Endourology, 2020, 34, 1256-1257.	1.1	0
651	Treatment of localized prostate cancer in elderly patients. Gland Surgery, 2015, 4, 283-7.	0.5	0
652	Association Between Alcohol Intake and Prostate Specific Antigen Screening: Results from a National Behavioral Survey. Urology, 2022, , .	0.5	0
653	Oncological Outcomes of cT1 and cT2 Micropapillary Variant Compared With cT1 and cT2 Conventional Urothelial Carcinoma Treated With Radical Cystectomy. Urology Practice, 0, , .	0.2	0